Florida-based drug developers, Biscayne Pharmaceuticals Inc. and Insero Health Inc., have merged to advance a synthetic version of a traditional Chinese medicine (TCM) – into phase Ib/IIa proof of concept in epilepsy by mid- to late 2016 and a cancer compound headed for investigational new drug application-enabling studies.